CA-AG v. Indivior

Indivior allegedly falsely marketed Suboxone, resulting in improper use of state Medicaid funds. According to CA-AG, from 2010 through 2015, Indivior promoted the sale and use of Suboxone to physicians who were writing prescriptions that lacked a legitimate medical purpose, were issued without any counseling or psychosocial support, and were for unsafe, ineffective, and medically unnecessary purposes; knowingly promoted the sale or use of Suboxone Sublingual Film based on false and misleading claims; and submitted a petition to the FDA on September 25, 2012, fraudulently claiming that the Suboxone Tablet had been discontinued “due to safety concerns” about the formulation of the drug and took other steps to fraudulently delay the entry of generic competition of Suboxone in order to improperly control pricing of Suboxone, including pricing to state Medicaid programs.

Summary generated from official California Attorney General press release